Dean Karalis, MD
Cardiovascular Disease · Philadelphia, PANPI 1609849256
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $301,736 of the $385,412 with a category attached, or 78.3%. 18 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 35.6% of the total. Reporting peaked in 2019 at $150,548 and has fallen 90.5% since, to $14,318 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $1036.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$137K
- Sanofi-aventis U.S. LLC$102K
- Amarin Pharma, Inc.$48K
- Novartis$30K
- Regeneron Healthcare Solutions, Inc.$30K
- Amgen$25K
- plus $13K from 12 others
Across 27 payments — averaging $3182.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$47K
- CSL Behring$30K
- Novartis$9K
- Amryt Pharma Holdings Ltd$282
- Chiesi USA, Inc.$120
What the payments were for
- Consulting fees$37,48310%
- Speaking & faculty fees$301,73678%
- Travel & lodging$35,9359%
- Food & beverage$9,9853%
- Education$2730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 111 | $137,032 |
| Sanofi-aventis U.S. LLC | 83 | $101,917 |
| Amarin Pharma, Inc. | 32 | $47,549 |
| Novartis | 35 | $30,439 |
| Regeneron Healthcare Solutions, Inc. | 36 | $30,164 |
| Amgen | 40 | $24,825 |
| Regeneron | 8 | $8,093 |
| AstraZeneca(2 entities) | 3 | $4,377 |
| Novo Nordisk | 9 | $252 |
| Idorsia Pharmaceuticals US Inc | 3 | $173 |
| Cleerly, Inc. | 1 | $127 |
| Kaneka Medical America LLC | 1 | $112 |
| Bridgebio Pharma, Inc. | 1 | $106 |
| Kestra Medical Technology Services, Inc. | 4 | $101 |
| Janssen Scientific Affairs, LLC | 2 | $70 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$385,412 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 268 | $300,475 |
| Repatha SureclickEvolocumab | 153 | $121,403 |
| XareltoRivaroxaban | 70 | $84,117 |
| EntrestoSacubitril/Valsartan | 49 | $60,196 |
| MounjaroTirzepatide | 52 | $54,002 |
| VascepaIcosapent Ethyl | 67 | $44,139 |
| LeqvioInclisiran Sodium | 12 | $40,741 |
| Icosapent Ethyl | 83 | $40,027 |
| OzempicSemaglutide | 35 | $38,330 |
| Repatha PushtronexEvolocumab | 48 | $36,603 |
| Praluent PenAlirocumab | 28 | $32,560 |
| NexlizetBempedoic Acid/Ezetimibe | 35 | $26,935 |
| Ezetimibe | 672 | $19,747 |
| Rosuvastatin Calcium | 617 | $11,088 |
| Ranolazine ErRanolazine | 114 | $10,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto, Leqvio | $30,439 | $100,93761 claims |
| Novo NordiskOzempic | $252 | $38,33035 claims |
| Esperion Therapeutics, Inc.Nexlizet | $137,032 | $26,93535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
- Brian DrachmanPhiladelphia$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.